Hoeki schreef op 4 november 2021 19:07:
Misschien heb ik het gemist, ik wist nooit dat er resultaten waren van het Roche programma.
$AFMD
Anyone has a link to the full text of the stuff I'm quoting below? The cut-off date is 6 months ago, it does not include the results for the 1850 mg cohort.
> Results: As of 30 April 2021, 21 patients received RO7297089 at 5 dose levels (60 mg [n=3], 180 mg [n=5], 360 mg [n=4], 1080 mg [n=6], and 1850 mg [n=3]...
> ...No DLTs or dose-dependent toxicities were reported...
> ...Preliminary PK assessments demonstrated a more than dose proportional increase in the exposure of RO7297089 with increasing dose levels from 60-1080 mg, suggesting non-linear PK and target-mediated drug disposition, with a trend to of approaching linear PK at doses higher than 1080 mg...
> ...Of the 18 response-evaluable patients, 1 patient experienced a partial response (1080 mg cohort) .... Ten patients had stable disease as their best response...
> ...There were no DLTs and a recommended phase 2 dose has not been identified
Gevonden op Stockwits